A new malaria vaccine candidate has been found to generate robust immune response while significantly delaying parasitemia in 59% of vaccinated subjects, according to a first-of-its-kind in-human study. Plasmodium vivax malaria is challenging to control because it can be dormant, causing no symptoms, and then become active causing symptomatic malaria weeks to months after initial infection.The vaccine candidate developed by researchers at Walter Reed Army Institute of Research (WRAIR) in US and tested jointly with GlaxoSmithKline (GSK) to prevent vivax malaria infection is the first in-human study of its kind under an investigation new drug application with the US Food and Drug Administration.
New malaria vaccine generates robust immune response
